Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
Administration, Cutaneous
Aged
Antineoplastic Agents
/ administration & dosage
Carcinoma, Squamous Cell
/ drug therapy
Graft Rejection
/ prevention & control
Humans
Imiquimod
/ administration & dosage
Immunocompromised Host
Immunosuppression Therapy
/ adverse effects
Infusions, Intralesional
Interleukin-2
/ administration & dosage
Kidney Transplantation
Liver Transplantation
Male
Neoplasm Recurrence, Local
/ drug therapy
Skin Neoplasms
/ drug therapy
Transplant Recipients
Treatment Outcome
aldara
cutaneous squamous cell carcinoma (cSCC)
imiquimod
interleukin-2 (IL2)
intralesional
intralesional IL-2
intralesional immunotherapy
organ transplant recipient
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
03
2021
accepted:
07
05
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer worldwide, with ever increasing incidence and mortality. While most patients can be treated successfully with surgical excision, cryotherapy, or radiation therapy, there exist a subset of patients with aggressive cSCC who lack adequate therapies. Among these patients are solid organ transplant recipients who due to their immunosuppression, develop cSCC at a dramatically increased rate compared to the normal population. The enhanced ability of the tumor to effectively undergo immune escape in these patients leads to more aggressive tumors with a propensity to recur and metastasize. Herein, we present a case of aggressive, multi-focal cSCC in a double organ transplant recipient to frame our discussion and current understanding of the immunobiology of cSCC. We consider factors that contribute to the significantly increased incidence of cSCC in the context of immunosuppression in this patient population. Finally, we briefly review current literature describing experience with localized therapies for cSCC and present a strong argument and rationale for consideration of an IL-2 based intra-lesional treatment strategy for cSCC, particularly in this immunosuppressed patient population.
Identifiants
pubmed: 34122442
doi: 10.3389/fimmu.2021.678028
pmc: PMC8190543
doi:
Substances chimiques
Antineoplastic Agents
0
Interleukin-2
0
Imiquimod
P1QW714R7M
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
678028Informations de copyright
Copyright © 2021 Vidovic, Simms, Pasternak, Walsh, Peltekian, Stein, Helyer and Giacomantonio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Int J Cancer. 1990 Sep 15;46(3):356-61
pubmed: 2394501
Cancers (Basel). 2020 May 22;12(5):
pubmed: 32455916
J Clin Aesthet Dermatol. 2010 Apr;3(4):39-48
pubmed: 20725546
J Surg Oncol. 2014 Nov;110(6):770-5
pubmed: 24996052
Int J Mol Sci. 2019 May 03;20(9):
pubmed: 31058839
Br J Dermatol. 2008 Sep;159(3):606-14
pubmed: 18616776
J Rheumatol. 2005 Nov;32(11):2130-5
pubmed: 16265690
J Am Acad Dermatol. 1992 Jun;26(6):976-90
pubmed: 1607418
Cancer Causes Control. 1997 May;8(3):271-83
pubmed: 9498892
Hum Immunol. 2017 Apr;78(4):327-335
pubmed: 28185865
Dermatol Surg. 2013 Sep;39(9):1306-16
pubmed: 23915332
Nat Rev Drug Discov. 2019 Mar;18(3):219-234
pubmed: 30679806
Cancer Res. 1993 Dec 1;53(23):5654-62
pubmed: 8242620
Clin Transplant. 2004 Aug;18(4):446-9
pubmed: 15233824
Expert Opin Pharmacother. 2014 Dec;15(18):2629-39
pubmed: 25381015
J Am Acad Dermatol. 2016 Mar;74(3):552-7
pubmed: 26577512
Oncoimmunology. 2012 Sep 1;1(6):908-916
pubmed: 23162758
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Dermatol Surg. 2004 Jan;30(1):116-20
pubmed: 14692941
JAMA Dermatol. 2019 Jul 1;155(7):819-825
pubmed: 30969315
Sci Rep. 2021 Feb 22;11(1):4337
pubmed: 33619293
Cancer. 1985 Apr 15;55(8):1629-32
pubmed: 4038911
J Biol Chem. 2010 Apr 9;285(15):11369-77
pubmed: 20154081
Cancer. 1990 Oct 15;66(8):1692-6
pubmed: 1698529
F1000Prime Rep. 2014 Aug 01;6:70
pubmed: 25165569
Transplantation. 2004 Jun 27;77(12):1777-82
pubmed: 15223891
J Am Acad Dermatol. 2006 Jun;54(6):1025-32
pubmed: 16713457
JAMA Dermatol. 2019 Jan 1;155(1):66-71
pubmed: 30516812
Front Immunol. 2019 Nov 29;10:2799
pubmed: 31849976
J Exp Med. 2008 Sep 29;205(10):2221-34
pubmed: 18794336
Transplantation. 2006 Dec 27;82(12):1792-3
pubmed: 17198278
J Am Acad Dermatol. 1989 Jan;20(1):71-4
pubmed: 2913082
Int J Dermatol. 1985 Dec;24(10):660-3
pubmed: 3910595
Laryngoscope. 2005 Sep;115(9):1561-7
pubmed: 16148695
Transplant Proc. 2006 Oct;38(8):2453-5
pubmed: 17097965
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
Lancet Oncol. 2008 Aug;9(8):713-20
pubmed: 18617440
Br J Dermatol. 2011 Nov;165(5):953-65
pubmed: 21729024
Nat Med. 1999 Nov;5(11):1303-7
pubmed: 10545998
J Am Acad Dermatol. 2007 Jun;56(6):989-93
pubmed: 17504715
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Nature. 1999 Feb 11;397(6719):530-4
pubmed: 10028970
Ann Oncol. 1994 Dec;5(10):957-60
pubmed: 7696170
Histol Histopathol. 2001 Jan;16(1):107-12
pubmed: 11193184
N Engl J Med. 2001 Mar 29;344(13):975-83
pubmed: 11274625
Head Neck. 2007 Jul;29(7):621-31
pubmed: 17230560
Br J Dermatol. 1983 Oct;109(4):449-52
pubmed: 6194810
J Clin Oncol. 2007 May 20;25(15):1974-8
pubmed: 17513803
Transplantation. 2005 Sep 27;80(6):749-58
pubmed: 16210961
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86
pubmed: 10025742
Int J Mol Sci. 2019 Apr 24;20(8):
pubmed: 31022866
Melanoma Res. 2011 Jun;21(3):235-43
pubmed: 21464773
Transplantation. 2009 Jan 27;87(2):157-63
pubmed: 19155967
Sci Rep. 2019 Nov 28;9(1):17754
pubmed: 31780824
JAMA Dermatol. 2017 Nov 1;153(11):1200
pubmed: 28975200
J Am Acad Dermatol. 2011 Feb;64(2):413-22
pubmed: 20334952
Transplantation. 1990 Mar;49(3):506-9
pubmed: 2316011
Clin Exp Dermatol. 2004 Sep;29(5):505-12
pubmed: 15347337
J Am Soc Nephrol. 2006 Feb;17(2):581-9
pubmed: 16434506
J Natl Cancer Inst. 2013 Mar 6;105(5):350-60
pubmed: 23291375
J Invest Dermatol. 1997 May;108(5):708-11
pubmed: 9129219
Histol Histopathol. 1993 Apr;8(2):219-26
pubmed: 7683937
Dermatol Ther. 2020 Nov;33(6):e14377
pubmed: 33030310
Exp Dermatol. 2014 Dec;23(12):902-8
pubmed: 25256412
J Am Acad Dermatol. 2001 Dec;45(6):953-6
pubmed: 11712048
J Am Acad Dermatol. 2004 Dec;51(6):1026
pubmed: 15583608
J Am Acad Dermatol. 2004 Nov;51(5 Suppl):S177-80
pubmed: 15577764
N Engl J Med. 1991 Sep 19;325(12):843-8
pubmed: 1875968
Nature. 2010 May 20;465(7296):368-72
pubmed: 20485437
Eur J Cancer. 1993;29A(4):520-4
pubmed: 8435203
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1639-43
pubmed: 17684139
J Clin Oncol. 2005 May 20;23(15):3421-32
pubmed: 15908653
J Cutan Pathol. 1990 Apr;17(2):65-71
pubmed: 2187024
J Am Acad Dermatol. 2018 Feb;78(2):249-261
pubmed: 29332705
Transplantation. 2008 Sep 27;86(6):880-4
pubmed: 18813114
J Natl Cancer Inst. 1983 Sep;71(3):439-47
pubmed: 6577218
JAMA. 2005 Aug 10;294(6):681-90
pubmed: 16091570
Arch Dermatol. 2009 Dec;145(12):1431-8
pubmed: 20026854
Int J Cancer. 2011 Jun 15;128(12):2803-14
pubmed: 20726000
J Natl Cancer Inst. 2004 May 5;96(9):709-11
pubmed: 15126608
Transplant Proc. 2003 Nov;35(7):2515-7
pubmed: 14611999
Oncologist. 2010;15(12):1320-8
pubmed: 21147868
Br J Cancer. 2009 Jan 13;100(1):200-5
pubmed: 19034275
J Invest Dermatol. 2009 Nov;129(11):2676-85
pubmed: 19516264
Eur Arch Otorhinolaryngol. 2004 Aug;261(7):359-68
pubmed: 14576946
J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S81-5
pubmed: 17052540
J Clin Oncol. 2005 Feb 1;23(4):759-65
pubmed: 15681519
J Immunol. 1995 Aug 15;155(4):2240-7
pubmed: 7636270
Cancer Control. 2016 Jan;23(1):12-20
pubmed: 27009452
Clin Cancer Res. 2012 Mar 1;18(5):1435-46
pubmed: 22261807
Hematol Oncol Clin North Am. 2019 Feb;33(1):1-12
pubmed: 30497667
J Clin Med. 2018 Jan 10;7(1):
pubmed: 29320468
J Clin Oncol. 2011 Sep 1;29(25):3419-26
pubmed: 21810686
J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):237-41
pubmed: 8335744
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19055-60
pubmed: 18025475
Lancet. 1998 Feb 28;351(9103):623-8
pubmed: 9500317
J Am Acad Dermatol. 2004 May;50(5 Suppl):S75-7
pubmed: 15097933
J Clin Invest. 2017 Jan 3;127(1):106-116
pubmed: 27869649
Int J Dermatol. 2018 Oct;57(10):1259-1264
pubmed: 30187924
N Engl J Med. 2018 Jul 26;379(4):341-351
pubmed: 29863979
Asia Pac J Oncol Nurs. 2019 Apr-Jun;6(2):154-160
pubmed: 30931360
Br J Cancer. 2001 Sep 1;85(5):683-6
pubmed: 11531252
Br J Dermatol. 1983 Oct;109(4):377-81
pubmed: 6414503
Arch Dermatol. 1992 Nov;128(11):1486-9
pubmed: 1444502
Lancet. 2009 May 2;373(9674):1525-31
pubmed: 19410716
J Invest Dermatol. 1991 Apr;96(4):408-13
pubmed: 1826122
Int J Cancer. 1995 Jan 17;60(2):183-9
pubmed: 7829213